SavedAdd your journal

Journals / Türk Fizyoterapi ve Rehabilitasyon / 2015 / Cilt: 26 - Sayı: 1

THE EFFECTS OF HIGH FREQUENCY CHEST WALL OSCILLATION IMPLEMENTATION IN PATIENTS WITH CYCTIC FIBROSIS

KİSTİK FİBROZİSLİ HASTALARDA YÜKSEK FREKANSLI GÖĞÜS DUVARI OSSİLASYONU UYGULAMASININ ETKİLERİ

Naciye YAĞLI VARDAR
Melda SAĞLAM
Hülya ARIKAN
Deniz İNCE İNAL
Ebru Çalık KÜTÜKÇÜ
Sema SAVCI
Zeynep ARIBAŞ
Ebru YALÇIN
Pages
32–39
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, there was a sig- nificant increase in flow rate of 25-75% of vital capacity - percent values of patients aftertreatment (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: The aim of the study was to evaluate the effects and personal use of short-termhigh frequency chest wall oscillation (HFCWO) implementation in patients with cystic fibrosis(CF).
📊
Key Findings & Data:Methods: Nine clinically stable patients with CF (mean age:15.0 ± 3.9 years) were enrolled inthe study.
💡
Conclusion & Impact:However, there was a sig- nificant increase in flow rate of 25-75% of vital capacity - percent values of patients aftertreatment (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: The aim of the study was to evaluate the effects and personal use of short-termhigh frequency chest wall oscillation (HFCWO) implementation in patients with cystic fibrosis(CF). Methods: Nine clinically stable patients with CF (mean age:15.0 ± 3.9 years) were enrolled inthe study. HFCWO implementation was performed 15 sessions, daily for 30 minutes. Respira- tory function and functional exercise capacity (6-minute walk test) of patients were assessedbefore and after treatment. Patients treatment methods that applied previously and prefe- rences between the applied methods, their opinions about satisfaction level and the treat- ment efficacy of HFCWO implementation according to the visual analog scale were recorded. Results: There were not statistically significant difference in pulmonary function test and6-minute walk test distance before and after treatment (p>0.05). However, there was a sig- nificant increase in flow rate of 25-75% of vital capacity - percent values of patients aftertreatment (p

Özet

Amaç: Kistik fibrozisli (KF) hastalarda kısa süreli yüksek frekanslı göğüs duvarı ossilasyonu(YFGDO) uygulamasının etkilerinin ve kişisel kullanımının değerlendirilmesiydi.Yöntemler: Klinik olarak stabil 9 KFli hasta (yaş ortalamaları 15.0±3.9 yıl) çalışmaya alındı.YFGDO uygulaması 15 seans boyunca günde bir kez 30 dakika süre ile yapıldı. Tedavi öncesive sonrası hastaların solunum fonksiyonları ve fonksiyonel egzersiz kapasiteleri (6 dakika yürüme testi) değerlendirildi. Hastaların daha önce uyguladıkları tedavi yöntemleri ve uygulananyöntemler arasındaki tercihleri, görsel analog skalasına göre YFGDO uygulaması memnuniyetdüzeyleri ve tedavinin etkinliği hakkındaki görüşleri kaydedildi.Sonuçlar: Tedavi öncesi ve sonrası solunum fonksiyon testi ve 6 dakika yürüme testi mesafesinde istatistiksel olarak anlamlı bir fark bulunmadı (p>0.05). Bununla birlikte, tedavisonrası hastaların zorlu vital kapasitenin %25-75 akım hızı yüzde değerlerinde anlamlı birartış saptandı (p

🔖

Cite This Article

VARDAR, N. Y., SAĞLAM, M., ARIKAN, H., İNAL, D. İ., KÜTÜKÇÜ, E. Ç., SAVCI, S., ARIBAŞ, Z., YALÇIN, E. (2022). THE EFFECTS OF HIGH FREQUENCY CHEST WALL OSCILLATION IMPLEMENTATION IN PATIENTS WITH CYCTIC FIBROSIS. Türk Fizyoterapi ve Rehabilitasyon, Cilt: 26 - Sayı: 1, 32–39. https://ajindex.com/articles/623419

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Bell SC, Robinson PJ. Cystic Fibrosis Standards of Care. Fitzge- rald AD, editör. Cystic Fibrosis Australia:Sydney, NSW, 2008
  2. Mason RJ, Broaddus VC, Murray JF, Nadel JA. Textbook of Respi- ratory Medicine. 1st ed. Philadelphia: Elsevier Saunders, 2005
  3. Shale DJ. Predicting survival in cystic fibrosis. Thorax. 1997;52(4):309
  4. Coakley RD, Boucher RC. Pathophysiology: epithelial cell biology and ion channel function in the lung, sweat gland and pancreas. In: Hodson M, Geddes D, Bush A, editors. Cystic fibrosis. 3rd ed. London: Hodder Arnold, 2007;p. 59-68
  5. Dodd ME, Prasad SA. Physiotherapy management of cystic fibrosis. Chron Respir Dis. 2005;2(3):139-49
  6. Gross D, Zidulka A, O’Brien C, Wight D, Fraser R, Rosenthal R, et al. Peripheral mucociliary clearance with high frequency chest wall compression. J Appl Physiol. 1985;58(4):1157-63
  7. Hansen LG, Warwick WJ. High frequency chest compression system to aid in mucous clearance in the lung. Biomed Instrum Technol. 1990;24(4):289-94
  8. Dosman CF, Jones RL. High frequency chest compression. A summary of the literature. Can Res J. 2005;12(1):37–41
  9. Bradley JM. High frequency chest wall ossilation in cystic fibrosis. Thorax. 2010;65(3):189-90
  10. Darbee JC, Kanga JF, Ohtake PJ. Physiologic evidence for high frequency chest wall ossilation and positive expiratory pressure breathing in hospitalized subjects with cystic fibrosis. Phys Ther. 2005;85(12):1278-89
  11. Oermann CM, Sockrider MM, Giles D, Sontag MK, Accurso FJ, Castile RG. Comparison of high frequency chest wall ossilation and ossilating positive expiratory pressure in the home management of cystic fibrosis: a pilot study. Pediatr Pulmonol. 2001;32(5):372-7
  12. Phillips GE, Pike SE, Jaffe A, Bush A. Comparison of active cyc- le of breathing and high-frequency ossilation jacket in children with cystic fibrosis. Pediatr Pulmonol. 2004;37(1):71-5
  13. World Health Organization, Physical status: the use and interp- retation of anthropometry, report of the WHO Expert Commit- tee, (WHO Technical Report Series, No: 854), Geneva, World He- alth Organization, 1995
  14. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstru- ctive pulmonary disease. Thorax. 1999;54(7):581-6
  15. Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R, et al. ATS/ERS Task Force. General considerations for lung function